Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Oncopeptides

1.78 SEK+0.79 %16.11, 12.56
Less than 1K followers

ONCO

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
+0.79 %
+2.12 %
+13.05 %
+5.62 %
-60.65 %
-64.53 %
-58.55 %
-63.80 %
-93.45 %

Oncopeptides is a biotechnology company developing drugs for difficult-to-treat hematological diseases. The company uses its PDC platform to develop peptide-linked drugs that selectively deliver cytotoxic agents into cancer cells. The company has drugs for commercialization, and has several drug candidates in development. Oncopeptides was founded in 2000 and is headquartered in Stockholm.

Read more
Market cap
794.39M SEK
Turnover
1.12M SEK
Revenue
71.12M
EBIT %
-315.87 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
All
Webcasts
Press releases
3rd party
ShowingAll content types

Forum discussions
Oncopeptides AB is a Swedish biotech company that, after a long development phase, has successfully developed and commercialized a drug called Pepaxti. This drug is intended for use in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have...
1/1/2026, 6:25 PM
by Hawkmountdiver
6
Q1 2026 Report is out Oncopeptides Oncopeptalks: Q1 report - Oncopeptides In the latest episode of Oncopeptalks, CEO Sofia Heigis and CFO Henrik Bergentoft comments on the Q1 report and other news presented during the week.
5/19/2026, 9:25 AM
by Hawkmountdiver
2
Good news about Pepaxti, and the share price reaction was in line with that. Three SEK was already surpassed momentarily. “STOCKHOLM — September 17, 2026 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that...
10/9/2026, 3:22 PM
by Hawkmountdiver
1
Q2 is out, a good quarter, and according to Redeye, the company will reach profitability without new share issues. https://www.redeye.se/research/1182339/oncopeptides-q2-initial-take-solid-23-q-q-growth?utm_source=finwire&utm_medium=RSS
8/27/2026, 8:42 AM
by Hawkmountdiver
0
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release09.11.2026, 14.02

Redeye: Oncopeptides (Q3 Update): Summer Dip Ahead of Third-Line Decision

Oncopeptides
Regulatory press release09.11.2026, 12.58

European Commission approves label expansion of Pepaxti to third-line treatment

Oncopeptides
Oncopeptides, Audiocast, Q3'26
Webcast05.11.2026, 09.00

Oncopeptides, Audiocast, Q3'26

Oncopeptides

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release05.11.2026, 08.00

Oncopeptides publishes Q3 report 2026

Oncopeptides
Press release04.11.2026, 16.00

New European real-world evidence supporting Pepaxti in heavily pretreated multiple myeloma to be presented at ASH 2026

Oncopeptides
Regulatory press release30.10.2026, 08.30

Number of shares and votes in Oncopeptides

Oncopeptides
Press release29.10.2026, 08.30

Invitation to presentation of the Q3 report 2026

Oncopeptides
Press release28.10.2026, 11.46

Redeye: Oncopeptides (Q3 Preview): Operating Leverage in Focus

Oncopeptides
Press release14.10.2026, 13.20

Redeye: Oncopeptides: SEK100m Directed Issue Funds Glioblastoma

Oncopeptides
Regulatory press release13.10.2026, 21.36

Oncopeptides completes a directed share issue of approximately SEK 100 million

Oncopeptides
Regulatory press release13.10.2026, 17.31

Oncopeptides intends to carry out a directed share issue of approximately SEK 100 million

Oncopeptides
Press release12.10.2026, 13.44

Redeye: Oncopeptides: PDC Platform Crosses the Blood-Brain Barrier

Oncopeptides
Oncopeptides, Investor Update, October 2026
Webcast12.10.2026, 08.00

Oncopeptides, Investor Update, October 2026

Oncopeptides
Press release09.10.2026, 13.30

Invitation to Oncopeptides’ investor webcast following positive glioblastoma data

Oncopeptides
Regulatory press release09.10.2026, 11.53

Oncopeptides confirms blood-brain-barrier penetration based on data from first patients in glioblastoma Window-of-Opportunity study

Oncopeptides
Press release22.09.2026, 08.30

Preclinical and translational glioblastoma data to be presented at EANO 2026, Oncopeptides nominated for prestigious EANO 2026 Poster award

Oncopeptides
Press release21.09.2026, 17.00

Oncopeptides to highlight clinical progress and present new data at the IMS Annual Meeting

Oncopeptides
Press release18.09.2026, 10.50

Redeye: Oncopeptides: CHMP Recommends Third-Line Treatment Extension

Oncopeptides
Regulatory press release17.09.2026, 17.35

CHMP issues positive opinion of label expansion of Pepaxti to third-line treatment

Oncopeptides
Press release31.08.2026, 16.45

Redeye: Oncopeptides (Q2 Update): Growth Continues, with CEE Region Unlocked

Oncopeptides